Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients.

[1]  H. Yamada,et al.  Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[2]  Y. Kagawa,et al.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients , 2012, European Journal of Clinical Pharmacology.

[3]  R. Bies,et al.  Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant Recipients , 2010, Antimicrobial Agents and Chemotherapy.

[4]  Kazuaki Matsumoto,et al.  Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. , 2009, International journal of antimicrobial agents.

[5]  K. Ho,et al.  An Update on C-reactive Protein for Intensivists , 2009, Anaesthesia and intensive care.

[6]  Honghao Zhou,et al.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers , 2009, European Journal of Clinical Pharmacology.

[7]  D. Andes,et al.  Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. , 2008, Therapeutic drug monitoring.

[8]  BJ Parker,et al.  High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus , 2007, Lupus.

[9]  W. L. Nelson,et al.  ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION , 2004, Drug Metabolism and Disposition.

[10]  J. Goldstein,et al.  Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. , 2003, Molecular pharmacology.

[11]  N. Wood,et al.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[12]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[13]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Margaret M Pearson,et al.  Voriconazole: A New Triazole Antifungal Agent , 2003, The Annals of pharmacotherapy.

[15]  A. Feldman,et al.  Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. , 2002, Journal of cardiac failure.

[16]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[17]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[18]  S. Clarke,et al.  Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response , 2002, British Journal of Cancer.

[19]  J. Pascussi,et al.  Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. , 2000, Biochemical and biophysical research communications.

[20]  G. Cheymol,et al.  Optimisation of Itraconazole Therapy Using Target Drug Concentrations , 1998, Clinical pharmacokinetics.

[21]  M. Lechner,et al.  Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid. , 1996, Molecular pharmacology.

[22]  C. Kasper,et al.  Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Maurel,et al.  Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture , 1995, Hepatology.

[24]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[25]  F. Frey,et al.  Impact of ketoconazole on the metabolism of prednisolone , 1989, Clinical pharmacology and therapeutics.

[26]  R. M. Tucker,et al.  Treatment of Mycoses with Itraconazole , 1988, Annals of the New York Academy of Sciences.

[27]  J. Graybill,et al.  Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[28]  B. McConkey,et al.  Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. , 1979, Annals of the rheumatic diseases.

[29]  Takahiro Yamada,et al.  Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application. , 2012, Clinical biochemistry.

[30]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[31]  D. Sin,et al.  Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. , 2005, Proceedings of the American Thoracic Society.

[32]  Kathleen A. Boyle,et al.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature , 2004, Mycopathologia.

[33]  Hongbing Wang,et al.  Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes , 2003, Clinical pharmacokinetics.